- Detail
- Parameters
- Review
ABBV-075 Mivebresib 1445993-26-9
Mivebresib is a potent and orally available bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a Ki of 1.5 nM.
| Cas No. | 1445993-26-9 |
Synonyms | Mivebresib |
Formula | C22H19F2N3O4S |
M.Wt | 459.47 |
Solubility | DMSO : 100 mg/mL (217.64 mM) |
Canonical SMILES | CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O |
Storage | Store at -20°C |
Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the TMPRSS2-ETS fusion proteins[1].
References:
[1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.